Skip to content
ABT·NYSE·US

Abbott

Abbott discovers, develops, manufactures, and sells a broad and diversified line of healthcare products, including branded generic pharmaceuticals, diagnostic systems and tests, pediatric and adult nutritional products, and medical devices for cardiovascular disease, diabetes care, and neuromodulation. It sells to wholesalers, distributors, government agencies, healthcare facilities, pharmacies, hospitals, retailers, consumers, and other institutions worldwide.

Source: SEC 10-K Feb 21, 2025

Recent Activity

Updated Oct 31, 2026
–Abbott Laboratories plans to separate its nutrition business into an independent company by the end of 2027, aiming to sharpen its focus on diagnostics and medical devices.
–Abbott cut its 2026 sales growth outlook.

Past updates are part of the Pro plan.

Thematic Position

ABT

Relationship Groups

Suppliers1
Partners2
Licensing1
Competitors3

Relationship details are part of the Pro plan.

Management Perspective on Regulatory & Geopolitical Developments

reimbursement policyprice control
Medicare DRG and PPS fixed reimbursement systems limit healthcare facility spending
SEC 10-KFeb 20, 2026

The full regulatory passage is part of the Pro plan.

1 more · Regulatory and geopolitical insights are part of the Pro plan.